Adipose-derived cells
Adipose-derived cells
复制标题
DOI：
10.3727/096368907783338190
复制
发表时间：
2007-01-01
影响因子：
3.3
通讯作者：
Serruys, Patrick W.
中科院分区：
文献类型：
--
作者：
Meliga, Emanuele;Strem, Brian M.;Serruys, Patrick W.
在西方国家，心力衰竭是最常见的住院原因，并带来沉重的经济后果。细胞疗法在组织再生中的应用前景广阔，并且越来越多地用于改善心脏病的预后。最近已经显示，脂肪组织除了定向成脂、内皮祖细胞和多能血管祖细胞之外，还含有多能细胞类型（脂肪源性干细胞，ADSC），其在细胞培养条件下已经显示具有令人印象深刻的发育可塑性，包括经历多谱系分化和自我更新的能力。ADSC表达多种CD标记抗原，类似于在MSC上观察到的那些，并且还能够分泌大量血管生成相关的细胞因子，包括血管内皮生长因子、粒细胞/巨噬细胞集落刺激因子、基质衍生因子-1 α和肝细胞生长因子。脂肪组织可以在身体的几个区域以最小的发病率大量收获，并且平均而言，100 ml人类脂肪组织产生约1 x 10（6）干细胞。在猪AMI模型中进行的研究显示LV功能显著改善，没有任何潜在致命性心律失常的报告。APOLLO试验是一项前瞻性、双盲、随机、安慰剂对照试验，目前处于招募阶段，是一项“首次人体”研究，旨在探讨急性MI患者ADSC移植的安全性和可行性。
Heart failure is by far the most common cause of hospitalization in Western countries, with onerous economic consequences. Cell therapy holds great promise for use in tissue regeneration and is increasingly used in an effort to improve outcomes in cardiac disease. Recently it has been shown that adipose tissue, in addition to committed adipogenic, endothelial progenitor cells and pluripotent vascular progenitor cells, also contains multipotent cell types (adipose-derived stem cells, ADSCs) that, in cell culture conditions, have shown to have an impressive developmental plasticity including the ability to undergo multilineage differentiation and self-renewal. ADSCs express multiple CD marker antigens similar to those observed on MSCs and are also capable of secreting a large number of angiogenesis-related cytokines, including vascular endothelial growth factor, granulocyte/macrophage colony stimulating factor, stromal-derived factor-1 alpha, and hepatocyte growth factor. Adipose tissue can be harvested in large quantities with minimal morbidity in several regions of the body and, on average, 100 ml of human adipose tissue yields about 1 x 10(6) stem cells. Studies conducted in porcine AMI models have shown a significant LV functional improvement, with no report of any potentially fatal arrhythmias. The APOLLO trial, a prospective, double blind, randomized, placebo-controlled trial currently in the recruiting phase, is a "first-in-man" study that explores the safety and feasibility of ADSC transplantation in patients with acute MI.